cytomegalovirus infection
Conditions
Interventions
test group:Receive foscarnet for prevention of cytomegalovirus infection from engraftment to day+60 after transplantation
control group:Receive ganciclovir for prevention of cytomegalovirus infection from engraftment to day+60 after transplantation
Sponsors
Department of hematology,Xinqiao Hospital,Third Military Medical University,Chongqing,China
Eligibility
Sex/Gender
All
Age
12 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Aged 12 to 55 years; 2. Patients undergoing allogeneic hematopoietic stem cell transplantation for hematology diseases; 3. Seronegative for CMV IgM; negative for CMV DNA in blood and urine; 4. Understand and voluntarily sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Absolute neutrophil count 105umol/L; ALT, AST and total bilirubin> 2 times upper limit of normal value; 3. Ongoing antiviral treatment with acyclovir,ganciclovir or foscarnet; 4. Allergy to foscarnet or ganciclovir; 5. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of CMV infection within 100 days after transplantation;Survival rate within 100 days after transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of CMV disease within 100 days after transplantation;Incidence of durg-related adverse events; | — |
Countries
China
Contacts
Public ContactXi Zhang
Department of hematology, Xinqiao Hospital, Third Military Medical University
Outcome results
None listed